List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Toll Like Receptor 8 (CD288 or TLR8) - Overview
Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics Development
Altimmune Inc
Ascendis Pharma A/S
Bolt Biotherapeutics Inc
Bristol-Myers Squibb Co
Curebiotech Inc
Curevac AG
Dynavax Technologies Corp
Eisai Co Ltd
Galderma SA
Gilead Sciences Inc
IngenoVax LLC
Janus Biotherapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
Merck KGaA
Nektar Therapeutics
Resolve Therapeutics LLC
Seven and Eight Biopharmaceuticals Corp
Shanghai De Novo Pharmatech Co Ltd
Shanghai Zhimeng Biopharma Inc
Silverback Therapeutics Inc
UroGen Pharma Ltd
Vaccex Inc
Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles
ALT-702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BDB-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BDC-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUCPT-8m - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products
Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products
Toll Like Receptor 8 (CD288 or TLR8) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1)
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Products under Development by Companies, H2 2020 (Contd..3), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Altimmune Inc, H2 2020
Pipeline by Ascendis Pharma A/S, H2 2020
Pipeline by Bolt Biotherapeutics Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020

List of Figures
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

Companies Mentioned
• Altimmune Inc
• Ascendis Pharma A/S
• Bolt Biotherapeutics Inc
• Bristol-Myers Squibb Co
• Curebiotech Inc
• Curevac AG
• Dynavax Technologies Corp
• Eisai Co Ltd
• Galderma SA
• Gilead Sciences Inc
• IngenoVax LLC
• Janus Biotherapeutics Inc
• Jiangsu Hengrui Medicine Co Ltd
• Merck KGaA
• Nektar Therapeutics
• Resolve Therapeutics LLC
• Seven and Eight Biopharmaceuticals Corp
• Shanghai De Novo Pharmatech Co Ltd
• Shanghai Zhimeng Biopharma Inc
• Silverback Therapeutics Inc
• UroGen Pharma Ltd
• Vaccex Inc